Previous studies have identified the NOD1/2-NF-κb/ERK and IL−8 signaling axis as a potential driver of cancer progression in cutaneous squamous cell carcinoma [12], suggesting similar mechanisms may operate in GBM. This evidence concerns the gene NOD1 and cutaneous squamous cell carcinoma.